TFAP2C expression in breast cancer: correlation with overall survival beyond 10 years of initial diagnosis

Breast Cancer Research and Treatment

Volumn 152, Issue 3, 2015, Pages 519-531

  Perkins, Susan M ^a   Bales, Casey ^a   Vladislav, Tudor ^a   Althouse, Sandra ^a   Miller, Kathy D ^a   Sandusky, George ^a   Badve, Sunil ^a   Nakshatri, Harikrishna ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Estrogen receptor; Outcome; TFAP2C

Indexed keywords

ACTIVATOR PROTEIN 2GAMMA; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MESSENGER RNA; PROGESTERONE RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR AP 2; UNCLASSIFIED DRUG; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; TFAP2C PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; SCORING SYSTEM; TISSUE MICROARRAY; TUMOR RECURRENCE; BREAST NEOPLASMS; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL ANALYSIS;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTOR AP-2;

EID: 84938399744     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3492-2     Document Type: Article

References (56)

1. Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9:631–643
2. Torres-Arzayus MI, Zhao J, Bronson R, Brown M (2010) Estrogen-dependent and estrogen-independent mechanisms contribute to AIB1-mediated tumor formation. Cancer Res 70:4102–4111
3. Hurtado A, Holmes KA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J, Howat WJ, Ali S, Carroll JS (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663–666
4. Wang J, Jarrett J, Huang CC, Satcher RL Jr, Levenson AS (2007) Identification of estrogen-responsive genes involved in breast cancer metastases to the bone. Clin Exp Metastasis 24:411–422
5. Wei B, Wang J, Bourne P, Yang Q, Hicks D, Bu H, Tang P (2008) Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas. Hum Pathol 39:1809–1815
6. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874
7. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346–352
8. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gomez H et al (2014) Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 20:1757–1767
9. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA et al (2013) ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 45:1439–1445
10. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L et al (2013) Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 45:1446–1451
11. Fuqua SA, Gu G, Rechoum Y (2014) Estrogen receptor (ER) alpha mutations in breast cancer: hidden in plain sight. Breast Cancer Res Treat 144:11–19
12. Nakshatri H, Badve S (2009) FOXA1 in breast cancer. Expert Rev Mol Med 11:e8
13. Carroll JS, Liu XS, Brodsky AS, Li W, Meyer CA, Szary AJ, Eeckhoute J, Shao W, Hestermann EV, Geistlinger TR et al (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122:33–43
14. Habashy HO, Powe DG, Rakha EA, Ball G, Paish C, Gee J, Nicholson RI, Ellis IO (2008) Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance. Eur J Cancer 44:1541–1551
15. Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S (2007) FOXA1 expression in breast cancer is associated with luminal subtype and good prognosis. J Clin Pathol 61:327–332
16. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H (2007) FOXA1 expression in breast cancer correlation with luminal subtype A and survival. Clin Cancer Res 13:4415–4421
17. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR et al (2012) Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481:389–393
18. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS (2011) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 43:27–33
19. Magnani L, Ballantyne EB, Zhang X, Lupien M (2011) PBX1 genomic pioneer function drives ERalpha signaling underlying progression in breast cancer. PLoS Genet 7:e1002368
20. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA, Wong J, Allred DC, Clark GM, Schiff R (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353–361
21. Anbalagan M, Rowan BG (2015) Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer. Mol Cell Endocrinol. doi:10.1016/j.mce.2015.01.016
22. Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS, Brown M et al (2010) Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications. Am J Pathol 176:2139–2149
23. Wierer M, Verde G, Pisano P, Molina H, Font-Mateu J, Di Croce L, Beato M (2013) PLK1 signaling in breast cancer cells cooperates with estrogen receptor-dependent gene transcription. Cell Rep 3:2021–2032
24. Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, Meszoely I, Mayer I, Abramson V, Ye F et al (2015) Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Res 75:405–414
25. Cyr AR, Kulak MV, Park JM, Bogachek MV, Spanheimer PM, Woodfield GW, White-Baer LS, O’Malley YQ, Sugg SL, Olivier AK et al (2015) TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. Oncogene 34:436–444
26. Woodfield GW, Chen Y, Bair TB, Domann FE, Weigel RJ (2010) Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells. Genes Chromosom Cancer 49:948–962
27. Orso F, Cottone E, Hasleton MD, Ibbitt JC, Sismondi P, Hurst HC, De Bortoli M (2004) Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5′-untranslated region. Biochem J 377:429–438
28. Tan SK, Lin ZH, Chang CW, Varang V, Chng KR, Pan YF, Yong EL, Sung WK, Cheung E (2011) AP-2gamma regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J 30:2569–2581
29. Caizzi L, Ferrero G, Cutrupi S, Cordero F, Ballare C, Miano V, Reineri S, Ricci L, Friard O, Testori A et al (2014) Genome-wide activity of unliganded estrogen receptor-alpha in breast cancer cells. Proc Natl Acad Sci USA 111:4892–4897
30. Gee JM, Eloranta JJ, Ibbitt JC, Robertson JF, Ellis IO, Williams T, Nicholson RI, Hurst HC (2009) Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J Pathol 217:32–41
31. Guler G, Iliopoulos D, Guler N, Himmetoglu C, Hayran M, Huebner K (2007) Wwox and Ap2gamma expression levels predict tamoxifen response. Clin Cancer Res 13:6115–6121
32. Friedrichs N, Jager R, Paggen E, Rudlowski C, Merkelbach-Bruse S, Schorle H, Buettner R (2005) Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer. Mod Pathol 18:431–438
33. Jager R, Friedrichs N, Heim I, Buttner R, Schorle H (2005) Dual role of AP-2gamma in ErbB-2-induced mammary tumorigenesis. Breast Cancer Res Treat 90:273–280
34. Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, Szymonifka J, Bhan AK, Shepherd LE, Zhang Y et al (2013) Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst 105:1036–1042
35. Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly C, Muller V, Schmidt S, Qi Y, Holtrich U et al (2013) Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Res 15:R86
36. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235
37. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2:416–422
38. Zhou Q, Dhungana B (2012) A SAS® Macro for biomarker analysis using maximally selected Chi square statistics with application in oncology. PharmaSUG 2012:SP12
39. Goswami CP, Nakshatri H (2014) PROGgeneV2: enhancements on the existing database. BMC Cancer 14:970
40. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404
41. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748–3757
42. Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451–1467
43. Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O’Driscoll L, Gallagher WM, Hennessy BT, Moriarty M, Crown J et al (2013) Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis 34:2300–2308
44. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102:13550–13555
45. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M (2008) The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 68:5405–5413
46. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA et al (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239–1246
47. Sarwar N, Kim JS, Jiang J, Peston D, Sinnett HD, Madden P, Gee JM, Nicholson RI, Lykkesfeldt AE, Shousha S et al (2006) Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression. Endocr Relat Cancer 13:851–861
48. Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S (2012) FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat 131:881–890
49. Habashy HO, Rakha EA, Aleskandarany M, Ahmed MA, Green AR, Ellis IO, Powe DG (2011) FOXO3a nuclear localisation is associated with good prognosis in luminal-like breast cancer. Breast Cancer Res Treat 129:11–21
50. Bogachek MV, Chen Y, Kulak MV, Woodfield GW, Cyr AR, Park JM, Spanheimer PM, Li Y, Li T, Weigel RJ (2014) Sumoylation pathway is required to maintain the basal breast cancer subtype. Cancer Cell 25:748–761
51. Wright TM, Wardell SE, Jasper JS, Stice JP, Safi R, Nelson ER, McDonnell DP (2014) Delineation of a FOXA1/ERalpha/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer. Mol Cancer Res 12:1829–1839
52. Nikolsky Y, Sviridov E, Yao J, Dosymbekov D, Ustyansky V, Kaznacheev V, Dezso Z, Mulvey L, Macconaill LE, Winckler W et al (2008) Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res 68:9532–9540
53. Yahata T, Shao W, Endoh H, Hur J, Coser KR, Sun H, Ueda Y, Kato S, Isselbacher KJ, Brown M, Shioda T (2001) Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding protein. Genes Dev 15:2598–2612
54. Howlin J, McBryan J, Napoletano S, Lambe T, McArdle E, Shioda T, Martin F (2006) CITED1 homozygous null mice display aberrant pubertal mammary ductal morphogenesis. Oncogene 25:1532–1542
55. Spanheimer PM, Woodfield GW, Cyr AR, Kulak MV, White-Baer LS, Bair TB, Weigel RJ (2013) Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor. Ann Surg Oncol 20:2204–2212
56. Wong PP, Miranda F, Chan KV, Berlato C, Hurst HC, Scibetta AG (2012) Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A). Mol Cell Biol 32:1633–1644